Long COVIDNEUROSTIM-LCNCT07709234
Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue
A study testing Transcranial Direct Current Stimulation in people with Long COVID and Post-COVID Conditions, run by University of Las Palmas de Gran Canaria.
Trial summary
Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may help modulate brain activity in regions… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Long COVID, Post-COVID Conditions, Fatigue
- What is being tested?
- Transcranial Direct Current Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 15 Sep 2026to 1 Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged between 18 and 70 years.
- Diagnosis of long COVID according to World Health Organization criteria, defined as symptoms persisting for at least three months after acute SARS-CoV-2 infection and lasting for a minimum of two months without an alternative explanation.
- Presence of persistent fatigue and/or cognitive impairment, commonly described as brain fog, attributed to long COVID and confirmed at screening.
- Stable clinical condition allowing participation in the intervention and assessment procedures.
- Ability to understand the study procedures and provide written informed consent.
Who cannot join
- Contraindications to transcranial direct current stimulation, including the presence of implanted electronic devices such as pacemakers or neurostimulators, intracranial metallic implants, or history of epilepsy or seizures.
- History of neurological disorders that may affect cognitive function, including stroke, Parkinson's disease, or neurodegenerative disorders.
- Pre-existing conditions associated with chronic fatigue or cognitive impairment prior to SARS-CoV-2 infection, such as fibromyalgia, chronic fatigue syndrome, or multiple sclerosis.
- Severe psychiatric disorders, including psychosis or severe depression.
- Substance abuse, including alcohol or drugs.
- Current oncological treatment with chemotherapy or radiotherapy.
- Pregnancy.
- Any medical condition that, in the opinion of the investigators, may interfere with participation or with the interpretation of the results.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Impact of Transcranial Direct Current Stimulation on Quality of Life, Brain Fog, and Fatigue in Patients With Long COVID: Study Protocol of the NEUROSTIM-LC Study
Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may help modulate brain activity in regions involved in cognition, fatigue, and executive function.
The NEUROSTIM-LC study will evaluate the feasibility and potential effects of repeated tDCS sessions in adults with long COVID presenting fatigue and/or brain fog. Participants will receive 30 sessions of tDCS applied over the left dorsolateral prefrontal cortex. Assessments will be performed before and after the intervention to evaluate changes in quality of life, fatigue, cognitive function, brain metabolism, physical performance, autonomic function, sleep quality, psychological symptoms, respiratory function, and blood biomarkers.
Read the detailed description
The NEUROSTIM-LC study is a prospective, single-arm, interventional before-and-after study designed to evaluate the feasibility, tolerability, and preliminary effects of transcranial direct current stimulation (tDCS) in patients with long COVID. The study will recruit adults aged 18 to 70 years diagnosed with long COVID according to World Health Organization criteria and presenting persistent fatigue and/or cognitive impairment commonly described as brain fog.
Participants will receive 30 sessions of tDCS delivered over consecutive weeks in a controlled clinical setting. Stimulation will be applied over the left dorsolateral prefrontal cortex, with the anode positioned at F3 according to the international 10-20 EEG system and the cathode over the contralateral supraorbital region. Each session will be delivered at 2 mA for 20 minutes. Sessions will be performed on weekdays under the supervision of trained healthcare professionals, and adherence, tolerability, and adverse effects will be monitored throughout the intervention period.
Assessments will be conducted at baseline and after completion of the intervention. Clinical outcomes will include health-related quality of life, fatigue, cognitive performance, sleep quality, anxiety and depression symptoms, and perceived symptom evolution. Neurobiological and physiological outcomes will include brain metabolism assessed by PET-CT, autonomic nervous system activity assessed by heart rate variability, exercise capacity assessed using the Ekblom-Bak submaximal cycle ergometer test, upper-limb muscle strength assessed by handgrip dynamometry, lower-limb neuromuscular performance assessed by countermovement jump testing, respiratory function, oxygen saturation, and routine blood biomarkers. Blood samples may also be stored for future analysis of inflammatory and oxidative stress markers.
The study aims to provide preliminary information on whether repeated tDCS may be associated with measurable improvements in fatigue, brain fog, quality of life, and physiological function in patients with long COVID. The findings will help inform the design of future controlled trials evaluating non-invasive neuromodulation strategies for persistent neurological and fatigue-related symptoms after COVID-19.
- Conditions
- Long COVID, Post-COVID Conditions, Fatigue, Cognitive Dysfunction
- Being tested
- Transcranial Direct Current Stimulation
- Keywords
- Transcranial direct current stimulation, tDCS, Brain fog, Long COVID, Chronic Fatigue, Quality of life, Cognitive impairment, Heart rate variability, PET-CT, Neuromodulation
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Fatigue, Cognitive Dysfunction, Mental Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial Direct Current StimulationDevice
Also called tDCS, Non-invasive brain stimulation, EPTE Bipolar tDCS device
Transcranial direct current stimulation will be delivered using a constant-current stimulator through surface electrodes placed over the scalp. The anode will be positioned over the left dorsolateral prefrontal cortex, corresponding to F3 according to the international 10-20 EEG system, and the cathode will be placed over the contralateral supraorbital region. Each session will be delivered at 2 mA for 20 minutes. Participants will complete 30 sessions.
| Study group | Role | What they receive |
|---|---|---|
| tDCS Intervention | Experimental | Participants will receive 30 sessions of transcranial direct current stimulation applied over the left dorsolateral prefrontal cortex. Stimulation will be delivered at 2 mA for 20 minutes per session, once daily, five days per week, under supervision of trained healthcare professionals. Receives: Device: Transcranial Direct Current Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in EuroQol 5-Dimension 5-Level Questionnaire Score
Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L assesses five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated across five levels of severity. Higher scores or index values reflect better health status, depending on the scoring method used. Changes from baseline to post-intervention will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Modified Fatigue Impact Scale Score
Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS). The MFIS assesses the impact of fatigue on physical, cognitive, and psychosocial functioning. The total score ranges from 0 to 84, with higher scores indicating greater fatigue impact. Changes from baseline to post-intervention will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Montreal Cognitive Assessment Score
Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The MoCA evaluates cognitive domains including attention, memory, language, visuospatial abilities, executive function, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. Changes from baseline to post-intervention will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Short Form-36 Health Survey Score
Health-related quality of life will be assessed using the Short Form-36 Health Survey (SF-36). The SF-36 evaluates eight domains of health-related quality of life: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Scores are transformed to a 0-100 scale, with higher scores indicating better health-related quality of life. Changes from baseline to post-intervention will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Verbal Fluency Task Performance
Verbal fluency will be assessed using verbal fluency tasks. Performance will be evaluated based on the number of correct words generated within the specified time period. Higher scores indicate better verbal fluency performance. Changes from baseline to post-intervention will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Stroop Test Performance
Executive function, inhibitory control, and cognitive flexibility will be assessed using the Stroop test. Performance will be evaluated using test-specific measures such as response accuracy and/or completion time. Better performance is reflected by higher accuracy and/or shorter completion time, depending on the scoring method used. Changes from baseline to post-intervention will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Secondary outcomes (7)
Change in Brain Metabolism
Brain metabolism will be assessed using positron emission tomography-computed tomography (PET-CT). Changes from baseline to post-intervention will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Heart Rate Variability
Autonomic nervous system activity will be assessed using heart rate variability (HRV) recorded under resting conditions. Time-domain, frequency-domain, and non-linear HRV indices will be evaluated to characterize changes in autonomic regulation.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Endurance Capacity
Endurance capacity will be assessed using the Ekblom-Bak submaximal cycle ergometer test. Heart rate responses, perceived exertion, estimated maximal oxygen uptake, and internal load will be evaluated under standardized conditions.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Handgrip Strength
Upper-limb muscle strength will be assessed using handgrip dynamometry. Participants will perform three maximal attempts, and the highest value will be used for analysis.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Lower-Limb Neuromuscular Performance
Lower-limb neuromuscular performance will be assessed using the countermovement jump test performed on a force platform. Variables related to force and power production will be evaluated.
Measured: Baseline and 3 days after completion of the 30-session tDCS intervention
Tolerability of the tDCS Intervention
Tolerability of the tDCS intervention will be assessed during each stimulation session using session monitoring records and participant reports. Tolerability will be evaluated based on the number of completed tDCS sessions out of the 30 scheduled sessions and the participant's ability to complete each session without clinically relevant discomfort. A higher number of completed sessions indicates greater intervention tolerability
Measured: During each tDCS session throughout the 30-session intervention period
Adverse Effects Related to tDCS
Adverse effects related to tDCS will be monitored and recorded at each stimulation session. Potential adverse effects include tingling, itching, headache, discomfort, burning sensation, dizziness, or transient erythema at the electrode site. The presence, type, and severity of adverse effects will be documented. Severity will be classified as mild, moderate, or severe.
Measured: During each tDCS session throughout the 30-session intervention period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start15 Sep 2026 (estimated)
- Primary completion22 Dec 2027 (estimated)
- Study completion1 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective single-arm before-and-after interventional study. All participants will receive transcranial direct current stimulation and will be assessed before and after the intervention.
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Las Palmas de Gran Canaria
- Sponsor type
- University, hospital or other
- Collaborators
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Canary Islands Health Service
- Responsible party
- Principal investigator, David Morales Álamo, University of Las Palmas de Gran Canaria
- Investigators
- Juan Francisco Vigueras, MD, Principal investigator, Canary Islands Health Service
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07709234
- Sponsor's protocol ID
- NEUROSTIM-LC-2026
- Other IDs
- CGC-2025-10415
- Acronym
- NEUROSTIM-LC
- Status last verified
- Jul 2026
- First submitted
- 11 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Transcranial Direct Current Stimulation on Quality of Life, Brain Fog, and Fatigue in Patients With Long COVID: Study Protocol of the NEUROSTIM-LC Study
- ClinicalTrials.gov ID
- NCT07709234
- Acronym / sponsor ID
- NEUROSTIM-LC / NEUROSTIM-LC-2026
- Conditions
- Long COVID, Post-COVID Conditions, Fatigue, Cognitive Dysfunction
- Keywords
- Transcranial direct current stimulation, tDCS, Brain fog, Long COVID, Chronic Fatigue, Quality of life, Cognitive impairment, Heart rate variability
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of Las Palmas de Gran CanariaUniversity, hospital or other
- Collaborators
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Canary Islands Health Service
- Study start
- 15 Sep 2026 (estimated)
- Primary completion
- 22 Dec 2027 (estimated)
- Study completion
- 1 Mar 2028 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may help modulate brain activity in regions involved in cognition, fatigue, and executive function.
The NEUROSTIM-LC study will evaluate the feasibility and potential effects of repeated tDCS sessions in adults with long COVID presenting fatigue and/or brain fog. Participants will receive 30 sessions of tDCS applied over the left dorsolateral prefrontal cortex. Assessments will be performed before and after the intervention to evaluate changes in quality of life, fatigue, cognitive function, brain metabolism, physical performance, autonomic function, sleep quality, psychological symptoms, respiratory function, and blood biomarkers.
Detailed description
The NEUROSTIM-LC study is a prospective, single-arm, interventional before-and-after study designed to evaluate the feasibility, tolerability, and preliminary effects of transcranial direct current stimulation (tDCS) in patients with long COVID. The study will recruit adults aged 18 to 70 years diagnosed with long COVID according to World Health Organization criteria and presenting persistent fatigue and/or cognitive impairment commonly described as brain fog.
Participants will receive 30 sessions of tDCS delivered over consecutive weeks in a controlled clinical setting. Stimulation will be applied over the left dorsolateral prefrontal cortex, with the anode positioned at F3 according to the international 10-20 EEG system and the cathode over the contralateral supraorbital region. Each session will be delivered at 2 mA for 20 minutes. Sessions will be performed on weekdays under the supervision of trained healthcare professionals, and adherence, tolerability, and adverse effects will be monitored throughout the intervention period.
Assessments will be conducted at baseline and after completion of the intervention. Clinical outcomes will include health-related quality of life, fatigue, cognitive performance, sleep quality, anxiety and depression symptoms, and perceived symptom evolution. Neurobiological and physiological outcomes will include brain metabolism assessed by PET-CT, autonomic nervous system activity assessed by heart rate variability, exercise capacity assessed using the Ekblom-Bak submaximal cycle ergometer test, upper-limb muscle strength assessed by handgrip dynamometry, lower-limb neuromuscular performance assessed by countermovement jump testing, respiratory function, oxygen saturation, and routine blood biomarkers. Blood samples may also be stored for future analysis of inflammatory and oxidative stress markers.
The study aims to provide preliminary information on whether repeated tDCS may be associated with measurable improvements in fatigue, brain fog, quality of life, and physiological function in patients with long COVID. The findings will help inform the design of future controlled trials evaluating non-invasive neuromodulation strategies for persistent neurological and fatigue-related symptoms after COVID-19.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective single-arm before-and-after interventional study. All participants will receive transcranial direct current stimulation and will be assessed before and after the intervention.
| Arm | Type | Receives |
|---|---|---|
| tDCS Intervention | Experimental | Device: Transcranial Direct Current StimulationParticipants will receive 30 sessions of transcranial direct current stimulation applied over the left dorsolateral prefrontal cortex. Stimulation will be delivered at 2 mA for 20 minutes per session, once daily, five days per week, under supervision of trained healthcare professionals. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults aged between 18 and 70 years.
- Diagnosis of long COVID according to World Health Organization criteria, defined as symptoms persisting for at least three months after acute SARS-CoV-2 infection and lasting for a minimum of two months without an alternative explanation.
- Presence of persistent fatigue and/or cognitive impairment, commonly described as brain fog, attributed to long COVID and confirmed at screening.
- Stable clinical condition allowing participation in the intervention and assessment procedures.
- Ability to understand the study procedures and provide written informed consent.
Key exclusion criteria (8 listed)
- Contraindications to transcranial direct current stimulation, including the presence of implanted electronic devices such as pacemakers or neurostimulators, intracranial metallic implants, or history of epilepsy or seizures.
- History of neurological disorders that may affect cognitive function, including stroke, Parkinson's disease, or neurodegenerative disorders.
- Pre-existing conditions associated with chronic fatigue or cognitive impairment prior to SARS-CoV-2 infection, such as fibromyalgia, chronic fatigue syndrome, or multiple sclerosis.
- Severe psychiatric disorders, including psychosis or severe depression.
- Substance abuse, including alcohol or drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial Direct Current StimulationAlso: tDCS, Non-invasive brain stimulation, EPTE Bipolar tDCS deviceTranscranial direct current stimulation will be delivered using a constant-current stimulator through surface electrodes placed over the scalp. The anode will be positioned over the left dorsolateral prefrontal cortex, corresponding to F3 according to the international 10-20 EEG system, and the cathode will be placed over the contralateral supraorbital region. Each session will be delivered at 2 mA for 20 minutes. Participants will complete 30 sessions. | Device | tDCS Intervention |
Primary outcome
Change in EuroQol 5-Dimension 5-Level Questionnaire Score
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L assesses five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated across five levels of severity. Higher scores or index values reflect better health status, depending on the scoring method used. Changes from baseline to post-intervention will be evaluated.
Change in Modified Fatigue Impact Scale Score
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS). The MFIS assesses the impact of fatigue on physical, cognitive, and psychosocial functioning. The total score ranges from 0 to 84, with higher scores indicating greater fatigue impact. Changes from baseline to post-intervention will be evaluated.
Change in Montreal Cognitive Assessment Score
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The MoCA evaluates cognitive domains including attention, memory, language, visuospatial abilities, executive function, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. Changes from baseline to post-intervention will be evaluated.
Change in Short Form-36 Health Survey Score
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Health-related quality of life will be assessed using the Short Form-36 Health Survey (SF-36). The SF-36 evaluates eight domains of health-related quality of life: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Scores are transformed to a 0-100 scale, with higher scores indicating better health-related quality of life. Changes from baseline to post-intervention will be evaluated.
Change in Verbal Fluency Task Performance
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Verbal fluency will be assessed using verbal fluency tasks. Performance will be evaluated based on the number of correct words generated within the specified time period. Higher scores indicate better verbal fluency performance. Changes from baseline to post-intervention will be evaluated.
Change in Stroop Test Performance
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Executive function, inhibitory control, and cognitive flexibility will be assessed using the Stroop test. Performance will be evaluated using test-specific measures such as response accuracy and/or completion time. Better performance is reflected by higher accuracy and/or shorter completion time, depending on the scoring method used. Changes from baseline to post-intervention will be evaluated.
7 secondary outcomes
Change in Brain Metabolism
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Heart Rate Variability
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Endurance Capacity
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Handgrip Strength
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Change in Lower-Limb Neuromuscular Performance
Time frame: Baseline and 3 days after completion of the 30-session tDCS intervention
Tolerability of the tDCS Intervention
Time frame: During each tDCS session throughout the 30-session intervention period
Adverse Effects Related to tDCS
Time frame: During each tDCS session throughout the 30-session intervention period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
Related trials for Long COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Juan Francisco Vigueras, MD principal investigator
Canary Islands Health Service
Questions about this trial
What is this clinical trial studying?
A study testing Transcranial Direct Current Stimulation in people with Long COVID and Post-COVID Conditions, run by University of Las Palmas de Gran Canaria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Juan Francisco Vigueras, MD (+34 606 63 86 98, juanfraviguerasperez@yahoo.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in EuroQol 5-Dimension 5-Level Questionnaire Score (time frame: Baseline and 3 days after completion of the 30-session tDCS intervention). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.